1. Cooper E, Corbett M, DeGayner Kuker M, Fabry D, Huskinsson R, Smith S. Improving access for patients with unmet medical needs—overview and best practice for success. A concept paper by the ISPE IP community of practice. 2014. http://www.ispe.org/concept-papers/improving-access-for-patients.pdf . Accessed 19 Nov 2014.
2. Department of Health and Human Services. Food and Drug Administration. Expanded access to investigational drugs for treatment use. Federal Register. 2009;74(155):40900–45. http://www.gpo.gov/fdsys/pkg/FR-2009-08-13/pdf/E9-19005.pdf . Accessed 19 Nov 2014.
3. Department of Health and Human Services. Food and Drug Administration. Guidance for industry. Expanded access to investigational drugs for treatment use—Qs & As. Draft guidance. 2013. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM351261.pdf . Accessed 19 Nov 2014.
4. Hoenen T, Feldmann H. Ebolavirus in West Africa, and the use of experimental therapies or vaccines. BMC Biol. 2014;12(1):80.
5. Sou H. EU compassionate use programmes (CUPs): regulatory framework and points to consider before CUP implementation. Pharm Med. 2010;24(4):223–9.